Back to top
more

Capricor Therapeutics (CAPR)

(Real Time Quote from BATS)

$5.02 USD

5.02
312,924

-0.03 (-0.59%)

Updated Apr 19, 2024 03:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 218.2% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%

by Zacks Equity Research

The mean of analysts' price targets for Capricor (CAPR) points to a 229.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how GSK (GSK) and Capricor Therapeutics (CAPR) have performed compared to their sector so far this year.

Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 261.3% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zimmer Biomet (ZBH) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 3.77% and 0.64%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Smart for Life, Inc. (SMFL) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Smart for Life, Inc. (SMFL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline

by Zacks Equity Research

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

After Plunging -52.01% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)

by Zacks Equity Research

Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Capricor (CAPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AdaptHealth Corp. (AHCO) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -35.71% and 0.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of -18.93% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Canopy Growth Corporation (CGC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -250% and 0.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

Forget Bargains, Play 5 Stocks With Rising P/E Instead

by Sanghamitra Saha

Forget undervalued stocks, there is room for upside even in stocks with rising P/E.

Here's Why Capricor (CAPR) is Poised for a Turnaround After Losing 19.3% in 4 Weeks

by Zacks Equity Research

Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Capricor (CAPR) delivered earnings and revenue surprises of 22.73% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength?

by Zacks Equity Research

Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Capricor Therapeutics (CAPR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Capricor (CAPR) delivered earnings and revenue surprises of 16.67% and -11.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis

by Debanjana Dey

Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.

Top Ranked Momentum Stocks to Buy for February 3rd

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 3rd

Top Ranked Momentum Stocks to Buy for January 28th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 28th

Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Capricor (CAPR) delivered earnings and revenue surprises of 38.57% and -35.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

CHF Solutions System to be Used in JAHVH Study After Final Nod

by Zacks Equity Research

CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.